|Bid||17.35 x 4000|
|Ask||27.00 x 3100|
|Day's Range||22.25 - 24.65|
|52 Week Range||11.93 - 25.63|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
LOS ANGELES, June 15, 2018 /PRNewswire/ -- California Cryobank, the world's leading donor sperm and donor egg bank, announced today that it has signed a definitive agreement for GI Partners, a private equity investment firm, to acquire the company from leading healthcare investors Longitude Capital and NovaQuest Capital. In a separate transaction announced today, GI Partners has also entered into a definitive agreement with AMAG Pharmaceuticals, Inc. (AMAG) to acquire Cord Blood Registry (CBR), the world's largest stem cell collection and storage company.
AMAG Pharmaceuticals, Inc. (AMAG) today announced it has entered into a definitive agreement to divest Cord Blood Registry (CBR®) to GI Partners, a private equity investment firm, for $530 million in an all cash sale. “The divestiture of CBR is an important step as we execute on AMAG's strategic plan, which includes leveraging our proven expertise in drug development and commercialization to bring innovative products to patients with unmet medical needs,” said William Heiden, president and chief executive officer at AMAG.
In today's pre-market research, four stocks are presented for scanning: AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and ArQule Inc. (NASDAQ: ARQL). Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. saw a slight decline of 0.62%, ending Tuesday's trading session at $23.95.
AMAG Pharmaceuticals, Inc. (AMAG) and March of Dimes today announced a strategic corporate partnership focused on a shared commitment to improve maternal health and birth outcomes, as well as to reduce health inequities. Through the partnership, AMAG will participate in the March of Dimes Prematurity Campaign Collaborative and support the expansion of the March of Dimes’ Supportive Pregnancy Care (SPC) model, an innovative group prenatal care program. “AMAG’s commitment to support the health of patients and families encompasses far more than the therapies we offer to help moms and babies.
AMAG Pharmaceuticals, Inc. (AMAG) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bremelanotide, a first-in-class melanocortin 4 receptor agonist designed for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The Prescription Drug User Fee Act (PDUFA) date for completion of FDA review of the bremelanotide NDA is March 23, 2019.
AMAG Pharmaceuticals, Inc. (AMAG) today announced that management will participate in the Jefferies 2018 Healthcare Conference on Tuesday, June 5th at 3:30 p.m. ET. AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine.
WALTHAM, Mass., May 09, 2018-- AMAG Pharmaceuticals, Inc. today commended the recent action taken by the Centers for Medicare and Medicaid Services to clarify statutory intent of section§ 1860 D-2 of the ...
LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Auris Medical Holding AG (NASDAQ: EARS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EARS as the Company's latest news hit the wire. On May 04, 2018, the Switzerland-based biopharmaceutical Company announced that the article reviewing the mechanism of action, pharmacokinetics and therapeutic applications of AM-111, the Company's investigational treatment for acute inner ear hearing loss, was published in Hearing Research, one of the leading journals in the otorhinolaryngology field. The peer-reviewed article "Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)" was published.
Strong first quarter execution with two FDA approvals and submission of a new drug application. Conference call scheduled for 8:00 a.m. ET today. WALTHAM, Mass., May 03, 2018-- AMAG Pharmaceuticals, Inc. ...
AMAG Pharmaceuticals, Inc. (AMAG) today announced the appointment of J. Alan Butcher as executive vice president and chief business officer effective immediately. In his role at AMAG, Mr. Butcher is responsible for leading the company’s overall business development efforts, with a focus on continuing to expand the portfolio with products that address unmet patient needs. Additionally, he oversees the company's alliance management team, and leads the corporate strategy function in close collaboration with Mr. Heiden, the senior leadership team, and the board of directors.
WALTHAM, Mass., April 27, 2018-- AMAG Pharmaceuticals, Inc. today announced that company management will participate in the following investor conferences:. Deutsche Bank Annual Health Care Conference ...
WALTHAM, Mass., April 26, 2018-- AMAG Pharmaceuticals, Inc. today announced that its first quarter 2018 financial results will be released on Thursday, May 3, 2018 before the U.S. financial markets open. ...
NEW YORK, April 24, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
WALTHAM, Mass., March 26, 2018-- AMAG Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for bremelanotide, which AMAG in-licensed ...
CRANBURY, N.J., March 26, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, announced today that its exclusive North American licensee for bremelanotide, AMAG Pharmaceuticals, Inc. (AMAG), has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bremelanotide for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. If approved, bremelanotide would become the first and only as desired pharmacologic option in the U.S. indicated for the treatment of HSDD in premenopausal women.
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 8:00 AM ...
LONDON, UK / ACCESSWIRE / February 20, 2018 / Active-Investors.com has just released a free research report on AMAG Pharma, Inc. (NASDAQ: AMAG) ("AMAG"). If you want access to this report all ...